AA
IKT icon

ALPS Advisors’s Inhibikase Therapeutics IKT Stock Holding History

ALPS Advisors’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
+134,002
New +$240K ﹤0.01% 1096

Other funds holding IKT

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
TCA
Transcend Capital Advisors Madison, New Jersey $1.48B AUM 25.55% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

ALPS Advisors's IKT Position: Q2 2026 in Review

ALPS Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 134,002 shares worth $272K. The stake represents ﹤0.01% of the portfolio and ranks #1096 among its holdings.

13 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • ALPS Advisors held 134,002 shares of Inhibikase Therapeutics worth $272K as of Q2 2026.
  • Inhibikase Therapeutics was a new ALPS Advisors position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1096 holding.
  • 13 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.